Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sutro Biopharma (STRO) Accumulated Expenses (2017 - 2025)

Sutro Biopharma's Accumulated Expenses history spans 9 years, with the latest figure at $34.7 million for Q3 2025.

  • For Q3 2025, Accumulated Expenses rose 7.91% year-over-year to $34.7 million; the TTM value through Sep 2025 reached $34.7 million, up 7.91%, while the annual FY2024 figure was $31.2 million, 18.77% down from the prior year.
  • Accumulated Expenses for Q3 2025 was $34.7 million at Sutro Biopharma, down from $38.2 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $38.5 million in Q4 2023 and bottomed at $4.5 million in Q1 2021.
  • The 5-year median for Accumulated Expenses is $11.6 million (2025), against an average of $18.1 million.
  • The largest annual shift saw Accumulated Expenses surged 493.86% in 2024 before it plummeted 69.39% in 2025.
  • A 5-year view of Accumulated Expenses shows it stood at $8.4 million in 2021, then skyrocketed by 56.42% to $13.1 million in 2022, then soared by 192.75% to $38.5 million in 2023, then decreased by 18.77% to $31.2 million in 2024, then rose by 10.96% to $34.7 million in 2025.
  • Per Business Quant, the three most recent readings for STRO's Accumulated Expenses are $34.7 million (Q3 2025), $38.2 million (Q2 2025), and $11.6 million (Q1 2025).